游离DNA与循环肿瘤DNA在肾癌和膀胱癌中的临床效用:当前文献的批判性综述
本综述检索至2020年8月15日的前瞻性与回顾性研究,评估cfDNA与ctDNA在膀胱癌和肾癌诊断、监测及预后中的价值。尿肿瘤DNA检测膀胱癌敏感性91%、特异性96%,优于膀胱镜和细胞学;ctDNA与cfDNA水平变化与疾病进展及生存相关。
要点
- 尿肿瘤DNA检测膀胱癌敏感性91%、特异性96%,优于膀胱镜和细胞学
- utDNA与ctDNA升高与非肌层浸润向肌层浸润进展相关
- 肾癌患者cfDNA显著高于健康对照或良性病变者,可测ctDNA与cfDNA升高与生存下降相关
核心结论
- 小样本研究汇总证据表明cfDNA与ctDNA可能在膀胱癌、上尿路尿路上皮癌和肾癌的检测、监测和预后中发挥作用。
研究设计与样本
- 通过2020年8月15日前的文献综述,纳入前瞻性和回顾性研究,检索词包括cell-free DNA、circulating tumor DNA、肾癌、膀胱癌等。
主要发现
- 尿肿瘤DNA检测膀胱癌敏感性91%、特异性96%,优于膀胱镜和细胞学。
- utDNA和ctDNA升高与非肌层浸润向肌层浸润疾病进展相关。
- 膀胱切除术患者中,ctDNA检测与较差总生存和无病生存相关,并与接受新辅助化疗后手术病理持续肿瘤相关。
- 肾癌患者cfDNA显著高于健康对照或良性病变者,可检测ctDNA和cfDNA升高与生存下降相关。
临床怎么用
- cfDNA与ctDNA可能作为膀胱癌和肾癌诊断、监测治疗反应及预后的工具,但需更多研究验证。
局限性
- 许多研究样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. OBJECTIVE: To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitoring, and prognostication of bladder and kidney cancer. EVIDENCE ACQUISITION: A literature review was conducted through August 15, 2020 including prospective and retrospective studies. Keywords included "cell-free DNA", "circulating tumor DNA", "kidney cancer", "renal cell carcinoma", "bladder cancer", "upper tract urothelial carcinoma", and "urothelial carcinoma". EVIDENCE SYNTHESIS: Urine tumor DNA (utDNA) has sensitivity of 91% and specificity of 96% for detecting bladder cancer, outperforming cystoscopy and cytology. Increased utDNA and ctDNA are associated with progression from non-muscle-invasive to muscle-invasive disease. In patients undergoing cystectomy, ctDNA detection is associated with worse overall survival and disease recurrence, and with persistent tumor on surgical pathology in those who received neoadjuvant chemotherapy. cfDNA is significantly higher in patients with kidney cancer than in healthy controls or in those with benign lesions, and detectable ctDNA and increased cfDNA are associated with decreased survival. CONCLUSIONS: Combined data from small studies provide evidence that cfDNA and ctDNA may have the ability to detect, monitor, and prognosticate in patients with bladder, upper tract urothelial, and kidney cancers. PATIENT SUMMARY: In this review, we looked at the work that has been published so far on cell-free and circulating tumor DNA in bladder and kidney cancers. We found that while many of the studies were small, there is evidence that cell-free tumor DNA can emerge as a tool for the diagnosis and monitoring of treatment response for patients with these cancers.
引用
- Green EA, Li R, Albiges L, et al. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021. PMID: 33975782. doi:10.1016/j.euo.2021.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。